We all get a little down with the suppressed SP. But, the company and management have done what they said they would do on the whole.
The conversation gets very interesting should there be primary and secondary outcome success in the trial.
Catalysts after this include re discussion with FDA and a price premium discussion with pharma in regards to its ICP lowering traits.
The first medication that has a direct action to do this (reduce ICP).
Then discussions re TBI, CVA, VP shunts, meningitis, hydrocephalus vertical markets come into the equation.
The TAMs of these make IIH look like a minnow.
That’s why I’m here. Success needed first in Evolve then the conversations for shareholders will be proper exciting.
Accumulating.
We all get a little down with the suppressed SP. But, the...
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.2¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.411M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 158 | 7.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.0¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.12pm 29/07/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable